Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective

Area of Science:

• Molecular biology
• Biophysics
• Pharmacology

Background:

• Cyclic AMP (cAMP) is a universal second messenger regulating cellular processes via proteins like PKA and EPAC.
• EPAC is implicated in various pathologies, driving the development of EPAC-specific inhibitors.
• Understanding EPAC inhibition mechanisms and potential aggregation-based inhibition (ABI) is crucial for drug development.

Purpose of the Study:

• To review the molecular basis of specific and non-specific interactions of EPAC antagonists.
• To discuss the role of aggregation-based inhibition (ABI) and its attenuators in EPAC inhibitor screening.
• To provide criteria for evaluating EPAC inhibitors and inform future drug development.

Main Methods:

• Biophysical analysis of EPAC inhibitor interactions.
• Review of literature on EPAC antagonists (CE3F4R and ESI-09).
• Discussion of aggregation-based inhibition (ABI) and attenuators (e.g., TX, HSA).

Main Results:

• CE3F4R acts as a non-competitive EPAC inhibitor, while ESI-09 is a competitive inhibitor.
• Hydrophobic EPAC inhibitors can form colloidal aggregates, leading to non-specific aggregation-based inhibition (ABI).
• Aggregation-based inhibition (ABI) attenuators can reduce false positives but may introduce false negatives.

Conclusions:

• A clear understanding of EPAC inhibitor interactions, including ABI, is essential for accurate drug screening.
• Biophysical evaluation is key to distinguishing specific inhibition from aggregation-based inhibition (ABI).
• This review provides criteria to guide the optimization of EPAC inhibitors and the development of next-generation therapeutics.